Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Mella

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Frontiers in Medicine|July 24, 2025
Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot studyØystein Fluge, Ingrid Gurvin Rekeland, Kari Sørland, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2018
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based StudyØystein Fluge, Bård Mannsåker, Anders Torp, et al.
Plos One|September 19, 2022
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patientsIngrid G Rekeland, Kari Sørland, Ove Bruland, et al.
Plos One|November 1, 2011
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled studyØystein Fluge, Ove Bruland, Kristin Risa, et al.
Translational Psychiatry|July 12, 2022
No replication of previously reported association with genetic variants in the T cell receptor alpha (TRA) locus for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)Marthe Ueland, Riad Hajdarevic, Olav Mella, et al.
Plos One|July 23, 2024
Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue SyndromeIngrid G Rekeland, Kari Sørland, Lisbeth Lykke Neteland, et al.
Cancers|February 15, 2022
Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal AdenocarcinomasBaard-Christian Schem, Frank Pfeffer, Martin Anton Ott, et al.
Plos One|July 2, 2015
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance TreatmentØystein Fluge, Kristin Risa, Sigrid Lunde, et al.
Molecular Neurobiology|October 10, 2018
Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Oliver P Günther, Jennifer L Gardy, Phillip Stafford, et al.
Brain, Behavior, and Immunity|September 25, 2015
Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue SyndromeMadlen Loebel, Patricia Grabowski, Harald Heidecke, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Medicine|July 24, 2025
Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot studyØystein Fluge, Ingrid Gurvin Rekeland, Kari Sørland, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2018
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based StudyØystein Fluge, Bård Mannsåker, Anders Torp, et al.
Plos One|September 19, 2022
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patientsIngrid G Rekeland, Kari Sørland, Ove Bruland, et al.
Plos One|November 1, 2011
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled studyØystein Fluge, Ove Bruland, Kristin Risa, et al.
Translational Psychiatry|July 12, 2022
No replication of previously reported association with genetic variants in the T cell receptor alpha (TRA) locus for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)Marthe Ueland, Riad Hajdarevic, Olav Mella, et al.
Plos One|July 23, 2024
Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue SyndromeIngrid G Rekeland, Kari Sørland, Lisbeth Lykke Neteland, et al.
Cancers|February 15, 2022
Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal AdenocarcinomasBaard-Christian Schem, Frank Pfeffer, Martin Anton Ott, et al.
Plos One|July 2, 2015
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance TreatmentØystein Fluge, Kristin Risa, Sigrid Lunde, et al.
Molecular Neurobiology|October 10, 2018
Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Oliver P Günther, Jennifer L Gardy, Phillip Stafford, et al.
Brain, Behavior, and Immunity|September 25, 2015
Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue SyndromeMadlen Loebel, Patricia Grabowski, Harald Heidecke, et al.
Pageof 5